Factory Acceptance Tests are used by manufacturers of industrial equipment or systems, as part of the manufacturing and quality assurance phases, to ensure that their products meet specified requirements and functionality before delivery to customers.
The completion of the Level 2 FAT by CPH2 was independently witnessed by Lagan MEICA the Principal Contactor and Arup, representative for Northern Ireland Water. It is a necessary stage of the process towards achieving final FAT, after which the electrolyser can be released for commercialisation and deployment.
CPH2 will now focus on completing the final Level 3 FAT, which will be independently witnessed by Lagan MEICA and Arup, before deployment to Northern Ireland Water.
The Level 2 FAT verified functionality of the MFE110 electrolyser and included end-to-end checks of control loops, electrical and mechanical plant, instrument calibration, and electrical installations in accordance with requirements. Functional testing of Programmable Logic Control functions on the physical system to demonstrate correct operation according to parameters was also completed.
This milestone marks the second of three stages within the FAT, which run sequentially. Level 3 FAT, the final testing procedure, will involve a formal demonstration of operation and performance witnessed by Lagan MEICA as well as Arup, a global engineering contractor.
The completed FAT of the MFE110 will be the first customer acceptance and validation of CPH2's scaled electrolyser technology, marking a significant moment for the development of Membrane-Free technology generally and a significant milestone in the Company's route to market.
“We continue to make solid, positive progress with another FAT stage successfully completed, and have now moved on to the final stage: Level 3 of the MFE110 FAT” said CPH2 CEO Jon Duffy. “As we reach this crucial turning point, I would like to extend my gratitude to our staff, shareholders and partners for their ongoing support during the FAT process, especially Lagan MEICA for their guidance. We look forward to updating the market once we have reached commercialisation in due course.”
For additional information:
